16th week of 2009 patent applcation highlights part 35 |
Patent application number | Title | Published |
20090098124 | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT HEAVY CHAINS AND METHODS OF USING SAME - The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant heavy chain, which variant heavy chain comprises constant domains from more than one IgG isotype. The variant heavy chain of the invention may further comprise at least one amino acid modification relative to the parental heavy chain, such that the Fc region of said variant heavy chain binds an FcγR with an altered affinity relative to a comparable molecule comprising the wild-type heavy cahin. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. | 2009-04-16 |
20090098125 | PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease - The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (such as breast, lung, prostate, melanoma and squamous) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents. | 2009-04-16 |
20090098126 | Method and kit for the detection of adenoviruses - A method for the simultaneous detection of adenoviruses of subgenera A, B, C, D, E and F in a sample comprising contacting said sample with at least one forward primer and at least one reverse primer for a hexon gene of an adenovirus of subgenera A, B, C, D, E and F and subjecting the sample contacted with said primers to a nucleic acid amplification technique. | 2009-04-16 |
20090098127 | Agents Capable of Downregulating an MSF-A DEPENDENT HIF-1ALPHA and Use Thereof in Cancer Treatment - Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or dissociating the MSF-A-HIF-1alpha protein complex, and methods of determining the prognosis of an individual having cancer by identifying the presence or absence of such a protein complex. | 2009-04-16 |
20090098128 | NPC1L1 orthologues - The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth. | 2009-04-16 |
20090098129 | Member of the TNF Ligand Family - The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of figure ( | 2009-04-16 |
20090098130 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS - The present invention provides GA targeting compounds which comprise GA targeting agent-linker conjugates linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions. | 2009-04-16 |
20090098131 | Compositions and methods for the treatment of immune related diseases - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2009-04-16 |
20090098132 | COMPOSITION AND METHOD FOR TREATING LUPUS NEPHRITIS - The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP0169 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses. | 2009-04-16 |
20090098133 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer - Compounds of a certain formula (I), | 2009-04-16 |
20090098134 | COMPOSITIONS AND METHODS FOR INHIBITING ENDOGENOUS IMMUNOGLOBULIN GENES AND PRODUCING TRANSGENIC HUMAN IDIOTYPE ANTIBODIES - The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced. | 2009-04-16 |
20090098135 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2009-04-16 |
20090098136 | USE OF TNF RECEPTOR ANTAGONISTS FOR TREATING DRY EYE - Methods of treating dry eye by administering inhibitors of tumor necrosis factor α (TNFα) are disclosed. | 2009-04-16 |
20090098137 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER - A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease. | 2009-04-16 |
20090098138 | DETECTION OF PROTEINS FROM CIRCULATING NEOPLASTIC CELLS - The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib. | 2009-04-16 |
20090098139 | Combination therapy for the treatment of neovascular disorders - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a combination of VEGF antagonists to the patient. The invention also features a pharmaceutical composition containing a first VEGF antagonist and a second VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2009-04-16 |
20090098140 | MONOCLONAL ANTIBODIES AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. These antibodies are of use to detect and isolate pancreatic cells or a subset thereof. The antibodies can be used for in vitro or in vivo detection and/or isolation of pancreatic endocrine cells. Methods of treating a pancreatic tumor are also disclosed. In several examples, the isolated monoclonal antibodies bind pancreatic endocrine cells and can be used to detect diabetes or a pancreatic endocrine cell tumor. | 2009-04-16 |
20090098141 | IL-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same - The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1α, IL-1β and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of insulin resistance associated pathologies) and for treating IL-1 haplotype associated insulin resistance associated pathologies. | 2009-04-16 |
20090098142 | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders - Methods and compositions for treating and/or monitoring treatment of IL-13-associated disorders or conditions are disclosed. | 2009-04-16 |
20090098143 | VACCINE PRODUCTION FOR PATHOGENIC BIRD VIRAL DISEASES - The present invention is an improved method for the production of vaccines to transmittable viral pathogens where the virus is pathogenic to the chicken embryos. Bird embryos are selected for vaccine production from wild and domestic birds, and preferably waterfowl, that have increased resistant to the viral pathogen. The invention is useful for native and engineered viruses. | 2009-04-16 |
20090098144 | IMMUNOGEN PRESENTING HIV GP120 V3 LOOP IN A CONFORMATION THAT INDUCES BROADLY NEUTRALIZING ANTIBODIES - Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related | 2009-04-16 |
20090098145 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY - Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. Provided are methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies. | 2009-04-16 |
20090098146 | METHODS TO DIAGNOSE A REQUIRED REGULATION OF TROPHOBLAST INVASION - Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β | 2009-04-16 |
20090098147 | Antibody fragment-polymer conjugates and uses of same - Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α | 2009-04-16 |
20090098148 | HIGH EFFICIENCY TISSUE-SPECIFIC COMPOUND DELIVERY SYSTEM USING STREPTAVADIN-PROTEIN A FUSION PROTEIN - The present invention relates to methods and compositions that can be employed to introduce toxins and nucleic acids into the cytoplasm or nucleus of a eukaryotic cell, particularly a cell of a higher vertebrate. The invention particularly concerns the use of a fusion protein of streptavidin and protein A sequences to form a non-covalent complex of a toxin or nucleic acid and an antibody. | 2009-04-16 |
20090098149 | TRANSGENIC ALGAE FOR DELIVERING ANTIGENS TO AN ANIMAL - Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter. In one illustrated embodiment, the biologically active protein is an antigenic epitope and upon administration to the animal the algal cell induces an immune response in the host animal. | 2009-04-16 |
20090098150 | Anti-acetylated huntingtin antibodies and uses therof - This invention includes, in part, methods of preparing acetylated Huntingtin (Htt) polypeptides, acetylated Htt polypeptide antigens, and antibodies that specifically recognize acetylated epitopes on Htt polypeptides. The invention also relates, in part, to the preparation and use of antibodies that specifically recognize and bind to acetylated epitopes on acetylated Htt polypeptides when an acetylated residue on the Htt polypeptide is a lysine that corresponds to K444 residue of full-length, wild-type Htt polypeptide. In some aspects, the invention includes hybridoma cell lines that produce antibodies that specifically bind acetylated Htt polypeptide and also includes antibodies and antigen-binding fragments thereof produced using polypeptides of the invention. | 2009-04-16 |
20090098151 | ALS-SPECIFIC PEPTIDE COMPOSITION - The invention relates to a composition for eliciting an immune response in an animal to produce an antibody that binds selectively to an amyotrophic lateral sclerosis (ALS)-specific epitope. | 2009-04-16 |
20090098152 | Vaccines Containing Canine Parvovirus Genetic Variants - Canine parvovirus vaccines and diagnostics and methods for their use are provided. | 2009-04-16 |
20090098153 | Activation of HCV-specific T cells - The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4 | 2009-04-16 |
20090098154 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 2009-04-16 |
20090098155 | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease - The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant. | 2009-04-16 |
20090098156 | Regimens for immunisation with meningococcal conjugates - Multivalent meningococcal conjugate vaccines are administered according to a schedule in which at least one or two doses are administered to a patient aged between 0 and 12 months, and a further dose is administered to a patient aged between 12 and 24 months. | 2009-04-16 |
20090098157 | Helicobacter Pylori Vaccination - A sterile immunogenic preparation of three purified | 2009-04-16 |
20090098158 | REDUCTION OF CONCOMITANT INFECTIONS IN PIGS BY THE USE OF PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 2009-04-16 |
20090098159 | Feline Cell Capable of Being Cultured Without Animal-Derived Protein, and Method for producing virus and method for producing vaccine using thereof - The present invention provides a cell strain which is derived from an fcwf-4 cell that is a cell derived from a feline whole fetus and which is capable of being cultured without animal-derived proteins, a method for producing the cell strain, and a method for producing a virus by using the cell. An inexpensive and safe feline vaccine can be produced according to the present invention. | 2009-04-16 |
20090098160 | Method of developing an immunogenic response using psoralen inactivated hiv - A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H. | 2009-04-16 |
20090098161 | Method of making an immunogenic composition using psoralen inactivated HIV - A method of making an immunogenic composition using inactivated HIV Inactivation of HIV is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. | 2009-04-16 |
20090098162 | Herpes simplex virus combined subunit vaccines and methods of use thereof - This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of vaccinating a subject against HSV and treating, impeding, inhibiting, reducing the incidence of, or suppressing an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 2009-04-16 |
20090098163 | Mutant F. turlarensis strain and uses thereof - A mutant strain of | 2009-04-16 |
20090098164 | Spore associated display - The present invention concerns spore display methods. More specifically, the invention concerns display of heterologous molecules, such as peptides and polypeptides, on spores of bacilli, such as, for example, | 2009-04-16 |
20090098165 | METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIAL INFECTION AND DISEASE - The present invention provides | 2009-04-16 |
20090098166 | Chimeric MSP-based malaria vaccine - The invention provides an immunogenic composition comprising MSP-8 linked to an antigen. Methods of using the composition to induce an immune response in an animal are also provided. | 2009-04-16 |
20090098167 | PHL P 1 Allergen Derivative - Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least three fragments comprises at least one T-cell epitope and said at least three fragments have a reduced allergenic activity or lack allergenic activity and rejoining said at least three fragments in an order differing from the order of the fragments in the wild-type allergen. | 2009-04-16 |
20090098168 | MULTIPLE-LAYER MICROBUBBLE LIPOSPHERE DRUG DELIVERY VEHICLE AND SYSTEM - A multiple layer microbubble drug delivery system, multiple layer microbubble drug delivery vehicle, method thereof and fabrication method is disclosed. The microfluidic drug delivery system for producing multiple layer microbubbles includes a first inlet which receives a gas and directs the gas into a central stream, a second inlet which receives a first liquid containing a drug substance and flow focuses the first liquid around the gas and a third inlet which receives a second liquid and flow focuses the second liquid around the first liquid. The multiple layer microbubble drug delivery vehicle includes a gas core, a first liquid layer containing a drug and surrounding the gas core and a second liquid layer surrounding the first liquid layer to stabilize the first liquid layer. | 2009-04-16 |
20090098169 | MODIFIED CLAY MINERAL - Modified clay minerals obtained by treating a clay mineral with a particular acylarginine derivative are useful for stabilizing emulsion compositions, inter alia, W/O emulsion composition, while hardly causing skin irritation, and providing moisture retention properties. | 2009-04-16 |
20090098170 | COSMETIC COMPOSITION COMPRISING SOLID ENTRAPPING PARTICLES FOR SUSTAINED RELEASE OF VOLATILE MATERIALS - The invention relates to a cosmetic composition comprising (a) solid entrapping particles having an average particle size from 5 to 200 micrometers and comprising (i) a copolymer obtainable by copolymerization of monomers of ethylene with at least one class of co-monomers comprising at least one heteroatom, (ii) a plasticizer comprising at least one heteroatom, and (iii) a volatile material; and (b) a cosmetically acceptable carrier. | 2009-04-16 |
20090098171 | Cosmetic composition in the form of an emulsion comprising a continuous aqueous phase and a dispersed fatty phase, and method for its preparation - The invention relates to a composition in the form of an emulsion comprising a continuous aqueous phase and a dispersed fatty phase, characterized in that said aqueous phase contains liposomes in the presence of a non-ionic surfactant chosen from fatty alcohol polyethylene glycol ethers and fatty alcohol polypropylene glycol ethers, and mixtures thereof, and of at least one polysaccharide in water-soluble form. | 2009-04-16 |
20090098172 | SURFACTANT, AND EMULSION COSMETIC AND LIPOSOME EACH CONTAINING THE SAME - The invention provides a surfactant comprising at least one trehalose-6-fatty acid ester selected from those represented by the following formula: | 2009-04-16 |
20090098173 | TOPICAL PAIN RELIEF PRODUCT - The present invention is directed to a topical composition comprising a counterirritant active ingredient and a sensate that provides a cooling sensation to the skin that is topically perceptible to an adult human subject for greater than about 90 minutes, e.g. greater than about 120 minutes, say greater than about 150 minutes, when applied in an effective amount over an area on the back of a hand, elbow, lower back or shoulder region. In one embodiment, the sensate can be encapsulated. The sensate can alternatively be bound to an ion exchange resin or adsorbed onto an adsorbant. | 2009-04-16 |
20090098174 | HEPARIN COATING OF BIOLOGICAL TISSUE - The present invention discloses an in vitro method to provide biological tissue with a heparin coating comprising the following steps; linking a biotin reagent to biological tissue, linking an avidin reagent to the biotinylated biological tissue, and linking a heparin reagent to the formed layer of avidin on the biological tissue thus forming a heparin coating. The invention further discloses a heparin coating on biological tissue, the use of a heparin coating, and the biological tissue coated with a heparin layer according to the method. | 2009-04-16 |
20090098175 | METHODS AND COMPOSITIONS FOR DELIVERY OF GROWTH FACTOR TO FIBROUS CONNECTIVE TISSUE - The presently disclosed subject matter relates to a peptide composition for non-covalently localizing fibrous connective tissue-inducing growth factor to a surface of an implant, the composition comprising a peptide having binding affinity for a surface material of an implant coupled to a peptide having binding affinity for a fibrous connective tissue-inducing growth factor. Methods are provided for delivering fibrous connective tissue-inducing growth factor GDF-7 in an amount effective to promote fibrous connective tissue repair and fibrous connective tissue formation. Also provided are methods of applying the peptide composition to an implant by contacting the composition with a surface of the implant; and kits comprising the compositions. | 2009-04-16 |
20090098176 | MEDICAL DEVICES WITH TRIGGERABLE BIOADHESIVE MATERIAL - Described herein are implantable medical devices comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue. The triggerable bioadhesive property of the polymer can be triggered or activated by exposure to a stimulus. Also, the present invention pertains to methods of making an implantable medical device comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue. | 2009-04-16 |
20090098177 | Methods and devices for tissue repair - Methods for treating diseased or damaged tissue in a subject are disclosed, involving administering to said subject at a site wherein diseased or damaged tissue occurs, cells of a type(s) normally found in healthy tissue corresponding to the diseased or damaged tissue, and/or suitable progenitor cells thereof, in association with bioresorbable beads or particles and optionally a gel and/or gel-forming substance. Where the cells an/or suitable progenitor cells thereof are chondrocytes, embryonic stem cells and/or bone marrow stromal cells, the methods of the invention are suitable for treating, for example, articular cartilage degeneration associated with primary osteoarthritis. Also disclosed is a device having tissue-like characteristics for treating diseased or damaged tissue in a subject, wherein the device comprises cells of a type(s) normally found in healthy tissue corresponding to the diseased or damaged tissue, and/or suitable progenitor cells thereof, in association with bioresorbable beads or particles and optionally a gel and/or gel-forming substance. | 2009-04-16 |
20090098178 | Porous Coating Loaded with a Liquid or a Solid Substance - The present invention relates to a process for manufacturing a porous coating with structures in the micro or nano-size domain characterized by the following steps: -providing a support having a surface, -depositing on said surface one mono-layer of temporary particles, -depositing a coating on said temporary particles in such a way that the thickness of said coating is less than the particle diameter, -eliminating said temporary particles and thereby obtaining a porous coating, the pores of said coating corresponding to the spaces previously occupied by the temporary particles and at least a pail of the pores communicating with the external environment, -applying a coating fixation step, characterized by the fact that it furthermore comprise a filling step where said pores are at least partially filled with a liquid or solid substance. The invention also concerns a coating and an object which can be obtained with this process. | 2009-04-16 |
20090098179 | FLUID EQUILBRATED ABSORBENT POLYMERIC MATERIALS, DEVICES INCLUDING SAME AND PACKAGING FOR SAME - Disclosed are methods and devices for the engineering, formation, and post-formation handling of absorbent polymeric materials. Devices intended for use in a fluid environment that include an absorbent polymeric material can be formed and processed to ensure that upon installation of the device, the polymeric material can not only have the desired physical characteristics for the intended use, but can also be pre-equilibrated for the environment in which the device will be utilized. In particular, the polymeric materials can be formed with particular characteristics such that, upon absorption of a fluid, the characteristics will alter in a predetermined way to provide the materials within target specifications during use. In addition, the materials can be stored in a fluid so as to exhibit the desired operating characteristics immediately upon installation. In one particular embodiment, the invention is directed to biocompatible, implantable devices designed for use in vivo. | 2009-04-16 |
20090098180 | FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM - The present invention relates to compounds of formula I and II, which are functionalized amino acids, and polymers formed from the same. | 2009-04-16 |
20090098181 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS - The invention is directed to triazolopyridazine compounds of Formula I: | 2009-04-16 |
20090098182 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. | 2009-04-16 |
20090098183 | MICROSPHERE-BASED MATERIALS WITH PREDEFINED 3D SPATIAL AND TEMPORAL CONTROL OF BIOMATERIALS, POROSITY AND/OR BIOACTIVE SIGNALS - A tissue engineering scaffold for growing cells can include a plurality of biocompatible microspheres linked together to form a three-dimensional matrix. The matrix can include a plurality of pores for growing cells. The biocompatible microspheres can include first and second sets of microspheres. The first set of microspheres can have a first characteristic, and a first predetermined spatial distribution with respect to the three-dimensional matrix. The second set of microspheres can have a second characteristic that is different from the first characteristic, and a second predetermined spatial distribution that is different from the first predetermined spatial distribution with respect to the three-dimensional matrix. The first and second characteristics can selected a composition, polymer, particle size, particle size distribution, type of bioactive agent, type of bioactive agent combination, bioactive agent concentration, amount of bioactive agent, rate of bioactive agent release, mechanical strength, flexibility, rigidity, color, radiotranslucency, radiopaqueness, or the like. | 2009-04-16 |
20090098184 | PROCESSES AND SYSTEMS FOR LOADING MEDICAL IMPLANTS WITH SIMULATIVE GROWTH AGENTS - Methods and systems for providing an improved apparatus and packaging system to more expeditiously hydrate or reconstitute medical grafts and to effectively and uniformly seed the medical grafts with biological components and cells. The systems generally comprise a container comprising entry port, at least one substrate cavity, and top, side and bottom walls defining an inner surface. The entry port is configured to receive the biological solution. The cavity is in communication with the entry port and includes the porous substrate maintained under negative pressure. The container volume is substantially the same as a volume of the porous substrate. The side and bottom walls are configured to promote a laminar flow of the biological solution received through the entry port. | 2009-04-16 |
20090098185 | Method for treating thrombotic disorders using sulfated polysaccharides - Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed. | 2009-04-16 |
20090098186 | METHOD AND SYSTEM FOR COATING A SURFACE OF A MEDICAL DEVICE WITH A THERAPEUTIC AGENT AND DRUG ELUTING MEDICAL DEVICES MADE THEREBY - A multi-layer drug coated medical device such as for example an expandable vascular drug eluting stent is formed by vacuum pulse spray techniques wherein each layer is irradiated to improve adhesion and/or drug elution properties prior to formation of subsequent layers. Layers may be homogeneous or of diverse drugs. Layers may incorporate a non-polymer elution-retarding material. Layers may alternate with one or more layers of non-polymer elution-retarding materials. Polymer binders and/or matrices are not used in the formation of the coatings, yet the pure drug coatings have good mechanical and elution rate properties. Systems, methods and medical device articles are disclosed. | 2009-04-16 |
20090098188 | Method for delivery of medication using a dissolvable device - A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of films made of a safe polymer material incorporating a medication that is released by dissolution of the film over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora. | 2009-04-16 |
20090098189 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE - The present invention relates to azaindoles of general formula I, a method for the production thereof, and to the use thereof for the production of pharmaceutical compositions. | 2009-04-16 |
20090098190 | Use of Lactobacillus for Increasing the Absorption of a Metal Chosen From Fe, Zn, Ca and Ions Thereof - The present invention relates to the use of at least one strain of | 2009-04-16 |
20090098191 | Use of bases to stabilize transdermal formulations - Stabilized transdermal acid sensitive drug formulations and their associated methods of production and use are described. The formulations containing acid sensitive drugs can also an acrylic adhesive, and a pharmaceutically acceptable base. The formulations can further contain other adhesives, permeation enhancers, and other stabilizing compounds such as free radical inhibitors. | 2009-04-16 |
20090098192 | Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same - A nonaqueous, extrudable composition includes at least one thermoplastic polymer in an amount of more than 20 wt % of the whole composition and tobacco. An extruded bioactive product in the form of a sheet can be made by extruding or hot melt shaping a nonaqueous composition comprising at least one thermoplastic polymer and a bioactive agent, the sheet being soluble in a user's mouth and resulting in sustained release of bioactive to the user. The sheet can be in a form that may be placed in contact with the mucosa of the user, and have an average dissolution time of 5 to 50 minutes for delivering the bioactive to the user. | 2009-04-16 |
20090098193 | HEMOSTATIC COMPOSITIONS AND METHODS FOR CONTROLLING BLEEDING - The disclosure provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions include an article containing cellulose, e.g., cotton gauze, and a cross-linked polysaccharide ionically linked to the cellulose. Methods of making and using the hemostatic compositions are also provided. | 2009-04-16 |
20090098194 | POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME - The present invention provides a method of treating a skin ailment including administering to a subject in need thereof, a therapeutically effective amount of a composition including (i) a primary diamine; (ii) a secondary aromatic diamine; (iii) a polyisocyanate; and (iv) optionally, a polyol. The present invention also provides a method of forming a skin bandage. | 2009-04-16 |
20090098195 | Influenza virus infection suppressor - The present invention is directed to providing influenza virus infection suppressors which contain a sialylgalactose-binding peptide, for example, a ganglioside GM3-binding peptide, as an active ingredient. Specifically, the invention provides influenza virus infection suppressors which contain the sialylgalactose-binding peptide of the following (a) or (b): (a) a peptide having the amino acid sequence of SEQ ID NO. 1 or 2; (b) a peptide having an amino acid sequence in which one or several nucleotides are deleted, substituted, or added, from/to the amino acid sequence of SEQ ID NO. 1 or 2, and having sialylgalactose-binding activity. | 2009-04-16 |
20090098196 | LIPID CARRIER COMPOSITIONS WITH REDUCED POLY-DISPERSITY - The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles. | 2009-04-16 |
20090098197 | CANCER VACCINE COMPRISING A CANCER ANTIGEN BASED ON THE PRODUCT OF A TUMOR SUPPRESSOR GENE WT1 AND A CATIONIC LIPOSOME - A cancer vaccine comprising a cancer antigen which comprises, as an active ingredient, the product of a tumor suppressor gene WT1, a partial peptide or a modified version thereof, and a cationic liposome. | 2009-04-16 |
20090098198 | Satiety - A capsule for suppressing appetite, comprising:
| 2009-04-16 |
20090098199 | METHODS OF TREATING GASTROINTESTINAL DISORDERS INDEPENDENT OF THE INTAKE OF FOOD - The present invention relates to a method of treating a gastrointestinal disorder by administering to a patient in need of treatment thereof a pharmaceutical composition, wherein said pharmaceutical composition can be administered to the patient independent of the intake of food. | 2009-04-16 |
20090098200 | COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION - Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media. | 2009-04-16 |
20090098201 | Composition and Method for Treatment and Prevention of Atherosclerosis - This invention relates to an oral composition for treatment or prevention of atherosclerosis comprising a low-dose aspirin and a low-dose of statin wherein the aspirin and statin are in a slow-release formulation. The invention also relates to a method of treatment or prevention of atherosclerosis using such a composition. | 2009-04-16 |
20090098202 | Extended Release Formulation - The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof. | 2009-04-16 |
20090098203 | Mucoadhesive Tetracycline Formulations - Mucositis is treated and/or prevented by administrating to a patient a formulation containing a tetracycline and at least one cationic polymer and/or mucoadhesive material. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. The formulation can be formed into liquid or solid dosage forms such as mouth rinse or tablet. Such compositions have the advantage of prolonged retention of the tetracycline in the mucosa of the oral cavity. | 2009-04-16 |
20090098204 | TISSUE IMPLANTS AND METHODS FOR MAKING AND USING SAME - The invention provides biocompatible, biodegradable calcium sulfate matrices containing calcium sulfate activated platelets for use in tissue formation. The matrices are particularly useful in stimulating hard tissue, for example, bone formation. The matrices may also further include a growth factor and/or a transfectable gene, the inclusion of which may be useful in stimulating the growth of tissue of interest. | 2009-04-16 |
20090098205 | pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES - The present invention provides a pH sensitive nanoparticulate delivery system for the administration of peptide hormones and drugs. In particular it provides a pH sensitive nanoparticulate for oral insulin administration. The nanoparticles developed by this process are fatty acid nanoparticles and a polymer is used as a stabilizer and also to incorporate pH sensitivity so that these particles shrink in the gastric acidic pH thereby protecting the incorporated insulin. These particles being also hydrophobic in nature and by virtue of their small size get absorbed through the intestinal cell wall and Peyer's patches. These nanoparticles are novel and unique in the sense that polymer content is only 0.03-0.06 g/g product and the polymer is hydrophilic in nature. | 2009-04-16 |
20090098206 | Particulate Metal Oxide - A particulate metal oxide having a median volume particle diameter in the range from 24 to 42 nm, a photogreying index in the range from 0.05 to 3 and/or and a yellowing index of less than 6. The dispersion can be used in a sunscreen product which is transparent, exhibits effective UV protection, reduced photoactivity, and reduced yellowing in combination with organic UV absorbers. | 2009-04-16 |
20090098207 | Technology for the Preparation of Microparticles - Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | 2009-04-16 |
20090098208 | PHARMACEUTICAL COMPOSITIONS BASED ON POROUS ZEOLITES AS RELEASE MEANS OF PHARMACOLOGICALLY ACTIVE MOLECULES AND RELATIVE USE - The present invention relates to pharmaceutical compositions for the oral administration of pharmacologically active molecules, comprising a release means consisting of porous zeolite in powder form, incorporating pharmacologically active molecules inside the pores and/or on its surface, the relative use for the preparation of drugs for oral administration, in particular for the treatment of inflammatory pathologies at an intestinal level and the preparation process of these compositions. | 2009-04-16 |
20090098209 | PHARMACEUTICAL COMPOSITIONS CONTAINING WATER-SOLUBLE DERIVATIVES OF PROPOFOL AND METHODS OF ADMINISTERING SAME VIA PULMONARY ADMINISTRATION - The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and sub-hypnotic states. | 2009-04-16 |
20090098210 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 2009-04-16 |
20090098211 | SOLID DOSAGE FORMS - Pharmaceutical dosage forms comprising tadalafil are described. Preferred dosage forms are bioequivalent to Cialis® notwithstanding a large particle size. | 2009-04-16 |
20090098212 | Acoustically sensitive drug delivery particle - Disclosed are ultrasound sensitive drug carrying particles, uses and methods thereof, wherein the drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon ultrasound exposure. | 2009-04-16 |
20090098213 | PAIN RELIEF AND SOOTHING CREAM AND METHOD FOR MAKING SAME - emollient and methyl salicylate, where said methyl salicylate comprises between 10 and 30 percent by weight of said cream; a skin stimulant comprising menthol crystals and two or more reactants selected from a group of camphor, cinnamomum cassia, diclofenac, eucalyptus, and ginger to cause a hot and cool stimulus on an epidermal surface; a pain reliever comprising two or more agents selected from a group of benzocaine, emu oil, eucalyptus oil, methylsulfonylmethane and glucosamine; and an inflammatory comprising two or more agents selected from a group of artemisia vulgaris, amica Montana flower extract, licorice root extract, oat extract, and thyme oil. | 2009-04-16 |
20090098214 | SKIN-REVITALIZING COSMETIC COMPOSITION - The invention provides a skin-revitalizing cosmetic composition for alleviating or eliminating skin problems such as dry skin, wrinkles, and age spots, the composition containing a skin-revitalizing agent at high concentration. The skin-revitalizing cosmetic composition contains a skin-revitalizing agent selected from the group consisting of aloe extract, placenta extract, hydrolyzed elastin, hydrolyzed collagen, and sodium hyaluronate, wherein the skin-revitalizing agent is in the form of nanoparticles obtained through a nanoparticle-forming treatment. | 2009-04-16 |
20090098215 | DIALYSIS SOLUTIONS CONTAINING PYROPHOSPHATES - Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate. | 2009-04-16 |
20090098216 | ARSENIC THERAPY FOR APLS-TYPE AUTOIMMUNE LYMPH-OPROLIFERATIVE SYNDROME IN MICE AND HUMANS - The invention relates to the use of an arsenic compound for the preparation of a medicament that is used to treat autoimmune diseases. | 2009-04-16 |
20090098217 | COMPOSITIONS AND METHODS FOR PROMOTING THICKER HAIR - The invention provides compositions for thickening hair comprising a celery product and optionally zinc. The invention also provides a method of thickening hair by administering to a person a composition containing a celery product, such as celery seed, celery powder, or celery extract. | 2009-04-16 |
20090098218 | Tetracyclic Lactame Derivatives - The present invention describes tetracyclic compounds of formula (IA) or (IB), | 2009-04-16 |
20090098219 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among is allantoin, divalent strontium salts, divalent zinc salts, monovalent sodium salts and the hydrated derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 2009-04-16 |
20090098220 | LIQUID PHARMACEUTICAL PREPARATION COMPRISING FORSKOLIN FOR PROMOTING LEAN BODY MASS - A liquid pharmaceutical preparation comprising forskolin in an amount of about 0.025 mg/ml to about 1 mg/ml of the liquid pharmaceutical preparation for promoting lean body mass in a human subject. Further, an effective amount of the liquid pharmaceutical preparation comprising forskolin is administered subcutaneously in the human subject. | 2009-04-16 |
20090098221 | Creatine ascorbyl derivatives and methods of use thereof - The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, muscular dystrophy, Charcot Marie Tooth syndrome, Alzheimer's disease, or creatine transporter defect) or a skin disorder, by administering a creatine-ascorbyl derivative. | 2009-04-16 |
20090098222 | Accelerating Agent of Calcium Absorption - The present invention provides an accelerating agent for calcium absorption comprising Gum Arabic, which is daily available while simultaneously taking dietary fiber. | 2009-04-16 |
20090098223 | NATURAL PLANT EXTRACT COMPOSITION FOR PREVENTION AND RECOVERY OF HYPERLIPIDEMIA AND STROKE, NATURAL TEA CONTAINING THE SAME AS ACTIVE INGREDIENT AND METHOD FOR PREPARING THE NATURAL TEA - A natural plant extract composition for the recovery and prevention of hyperlipidemia and stroke, a natural tea comprising the same as an active ingredient, and a method for preparing the natural tea. The natural plant extract composition contains a | 2009-04-16 |
20090098224 | Metabolic enhancing properties of theaflavins and thearubigins - Naturally occurring or synthetically derived theaflavins and thearubigins are disclosed which are orally active and have novel and specific metabolic enhancing effects in humans. The inventors have discovered that theaflavins and thearubigins decrease appetite, reduce adipose tissue, increase metabolism and energy levels and protect and enhance lean body mass. | 2009-04-16 |